25. Progressive multifocal leukoencephalopathy Clinical trials / Disease details

Clinical trials : 26 / Drugs : 35 - (DrugBank : 22) / Drug target genes : 8 - Drug target pathways : 37

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2010-020369-26-DE (EUCTR)	29/11/2010	18/08/2010	High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab	High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab	Immune Reconstitution Inflammatory Syndrome MedDRA version: 12.1;Level: PT;Classification code 10054014;Term: Immune reconstitution syndrome	Product Name: methylprednisolone INN or Proposed INN: METHYLPREDNISOLONE Product Name: prednisolone INN or Proposed INN: PREDNISOLONE Product Name: prednisolone INN or Proposed INN: PREDNISOLONE Product Name: prednisolone INN or Proposed INN: PREDNISOLONE Product Name: prednisolone INN or Proposed INN: PREDNISOLONE Product Name: prednisolone INN or Proposed INN: PREDNISOLONE Product Name: prednisolone INN or Proposed INN: PREDNISOLONE	Biogen Idec	NULL	Not Recruiting			Female: yes Male: yes	20		Germany
2	NCT01211665 (ClinicalTrials.gov)	September 2010	29/7/2010	Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)	High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab	Immune Reconstitution Inflammatory Syndrome;Leukoencephalopathy, Progressive Multifocal	Drug: Methylprednisolone;Drug: Prednisolone	Biogen	Elan Pharmaceuticals	Terminated	18 Years	N/A	All	3	Phase 4	United States;Germany